Seroatlas · Human Serome Atlas

LINC01590

Putative uncharacterized protein encoded by LINC01590

Also known as: CF164_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5TEZ4
Gene: LINC01590
Canonical length: 76 aa

OverviewNCBI Gene

No narrative summary is available for LINC01590 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

76 residues, UniProt reviewed canonical sequence.

>Q5TEZ4|LINC01590
     1  MSHLPAVSPV FFQLPAPHPP TVLRPQLGLH PNPECDREKM SVRDHDPEVL TRNSACKPRG
    61  QLSGHLLKPR APLEAA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LINC01590 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.71

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LINC01590 as an antibody target. Whether an autoantibody or antibody against LINC01590 could matter depends on whether native LINC01590 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LINC01590 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label LINC01590 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...